A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR ...

CRISPR Therapeutics AG (CRSP) closed at $41.17 in the latest trading session, marking a -1.84% move from the prior day.

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases.

Bioengineering professor and The Grainger College of Engineering's Dean, Rashid Bashir, led a team of researchers in a project that's resulted in new technology that offers rapid, highly sensitive ...

CRISPR gene-editing technology offers the possibility of creating disease-resistant species, potentially eliminating deadly ...

CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

CRISPR libraries enable scientists to systematically investigate gene functions, identify novel drug targets, and develop personalized therapies.

While technology and medicine have ... There is no doubt that CRISPR and CAR-T cell therapy are breakthroughs in the medical field. But because they are still in their initial stages, they come ...

The researchers applied CRISPR gene technology to investigate whether activating an entire ... Gene and Cell Therapy and induction as a Fellow of the American Institute for Medical and Biological ...